Unbiased Analysis of Today's Healthcare Issues
That is the topic of an Evidence Base article out today titled “Reflecting on 2025, looking to 2026: Experts outline what to expect for drug pricing and market access“. In the article, a variety of experts reflect on how 2025 reshaped the global drug pricing and market access landscape as well as predict what to…
That is the tile of my recent paper in the Journal of Medical Economics with co-authors Kyi-Sin Than, Sanjana Muthukrishnan, Jincy Paulose, Ver Bilano and Nicholas Kuypers. The abstract is below: ObjectiveParoxysmal nocturnal hemoglobinuria (PNH) is a rare and debilitating hematological disease with significant economic burden. Despite the availability of multiple therapies, there is a…
As we start off 2026, I wanted to quickly look back at the research that I published in peer-reviewed journals last year. Here’s the list: Shafrin J, Jadhav K, Warren C, Quddus S, Zawadzki N, Yang D, Damon A, Spurrier K, Batt K, Wei D. Chronic myeloid leukemia treatment intolerance imposes additional resource and economic…
In my latest Guest Column in The Evidence Base, II am joined by my colleague Tiago Beck as we examine how global pricing reforms are reshaping the European pharmaceutical landscape. Building on their session at ISPOR Europe 2025, the column explores the growing tension between EU access ambitions and international policy pressures – offering a…
That is the title of a new paper out last week in Future Oncology with co-authors Kejal Jadhav, Cheryl Warren, Sabiha Quddus, Nadine Zawadzki, Daisy Yang, Andrea Damon, Kathryn Spurrier, Katharine Batt and David Wei. The abstract is below. ObjectiveTyrosine kinase inhibitors (TKIs) have transformed the prognosis of chronic myeloid leukemia (CML) into a manageable…
That is the title of my new publication out today with the subtitle “A case study of rifaximin for the treatment of overt hepatic encephalopathy using QALY and non-QALY measures“. This was work with co-authors Shanshan Wang, Leonardo Passos Chaves, Olamide Olujohungbe, Sanjana Muthukrishnan, and Aditi Chaudhary. The abstract is below. BackgroundTraditional cost effectiveness analyses…
That is the title of a paper published today in Future Oncology with co-authors Erin Mulvey, Kyi-Sin Than, Sanjana Muthukrishnan, Alex Mutebi, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, Diala Harb, Victor Gonzalez, Sarah Quinlan, Vardhaman Patel and Patrick Connor Johnson. The study was conducted in collaboration with the Lymphoma Research Foundation. The abstract is below:…
That is the title of a new paper out in Value in Health with co-authors Jaehong Kim, Jacob Fajnor, Kyi-Sin Than, Elizabeth S. Mearns , Stacey L. Kowal, Thomas Majda and Jakub P. Hlávka PhD. The abstract is below. Objectives To quantify how incorporating patient risk preferences and severity adjustments affect the value of a…
That is the title of a paper published today in Current Medical Research and Opinion with co-authors Nadine Zawadzki, Moises Marin, Ivana Audhya, Lauren Sedita, Natasha Kulkarni and Alexa Klimchak. The abstract is below. ObjectivesQuantify caregiver risk preferences to inform the “value of hope” for Duchenne muscular dystrophy (DMD) therapies affecting time to loss of…
Payers will often look to disease analogs when making pricing and coverage decisions. These disease analogs can inform the level of rebates, need for prior authorization/utilization management, and the drug’s cost sharing tier. Traditionally, however, disease analogs are selected on an ad hoc basis. In a recent JMCP paper titled “A structured approach for identifying…